UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Holdings in Personalis, Inc. $PSNL

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Personalis, Inc. (NASDAQ:PSNL) by 7,822.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 87,068 shares of the company’s stock after buying an additional 85,969 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Personalis were worth $1,167,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Merck & Co. Inc. purchased a new position in shares of Personalis in the second quarter valued at about $188,202,236. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Personalis by 273.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock worth $85,812,000 after purchasing an additional 7,896,714 shares during the period. BlackRock Inc. purchased a new stake in shares of Personalis during the second quarter worth about $94,905,000. Bank of America Corp DE bought a new stake in shares of Personalis in the second quarter worth about $24,395,000. Finally, AIGH Capital Management LLC bought a new stake in shares of Personalis in the second quarter worth about $22,981,000. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Christopher Hall sold 100,000 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $15.08, for a total value of $1,508,000.00. Following the sale, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $3,558,668.88. This represents a 29.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $14.00, for a total transaction of $69,748.00. Following the completion of the transaction, the chief financial officer owned 198,833 shares of the company’s stock, valued at approximately $2,783,662. The trade was a 2.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 256,233 shares of company stock worth $3,568,236. Company insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on PSNL shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research report on Friday, July 17th. Craig Hallum lowered Personalis from a “buy” rating to a “hold” rating and set a $16.25 price objective on the stock. in a research report on Monday, August 24th. Zacks Research raised Personalis from a “strong sell” rating to a “hold” rating in a research note on Monday, September 7th. BTIG Research upped their target price on Personalis from $11.00 to $16.25 and gave the company a “buy” rating in a report on Monday, July 20th. Finally, Needham & Company LLC lowered Personalis from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $14.54.

Personalis Price Performance

Shares of PSNL opened at $16.21 on Friday. The company has a 50-day simple moving average of $14.84 and a two-hundred day simple moving average of $10.56. The firm has a market capitalization of $1.70 billion, a PE ratio of -14.87 and a beta of 2.31. Personalis, Inc. has a one year low of $4.95 and a one year high of $18.89.

Personalis (NASDAQ:PSNL) last released its earnings results on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. The firm had revenue of $22.36 million during the quarter, compared to analysts’ expectations of $16.69 million. Analysts expect that Personalis, Inc. will post -1.07 EPS for the current fiscal year.

Personalis Profile

Personalis, Inc is a genomics company focused on precision oncology and advanced molecular testing. The company develops and commercializes genomic products designed to help identify, monitor and characterize cancer, supporting more informed treatment decisions and the development of targeted therapies.

Its offerings include tissue- and blood-based tumor profiling, liquid biopsy testing and immune profiling. Personalis’ technologies are designed to detect and track tumor-derived signals, evaluate genomic alterations and provide insights into the interaction between cancer and the immune system.